Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.81 |
| ▸ | GAA | P10253 | 3/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.81 |
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | XBP1 | P17861 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332413 | 0.93 | KMT2A (0.72) | KMT2AGAANPSR1CSNK2A1KDM4E | |
| SCHEMBL3333973 | 0.83 | CSNK2A1 (0.84) | KMT2AGAACSNK2A1KDM4EHSD17B10 | |
| SCHEMBL3331372 | 0.83 | CSNK2A1 (0.68) | KMT2AGAANPSR1CSNK2A1KDM4E | |
| SCHEMBL11940597 | 0.82 | CSNK2A1 (0.79) | KMT2AGAANPSR1CSNK2A1KDM4E | |
| SCHEMBL14260531 | 0.81 | GAA (0.55) | KMT2AGAANPSR1CSNK2A1KDM4E | |
| SCHEMBL12288530 | 0.80 | CSNK2A1 (0.68) | KMT2AGAANPSR1CSNK2A1KDM4E | |
| SCHEMBL11939089 | 0.80 | CSNK2A1 (0.67) | KMT2AGAANPSR1CSNK2A1KDM4E | |
| SCHEMBL3334350 | 0.79 | CSNK2A1 (0.74) | KMT2AGAACSNK2A1KDM4EHSD17B10 | |
| SCHEMBL11939631 | 0.79 | PIK3CD (0.82) | KMT2ACSNK2A1KDM4EHSD17B10HPGD | |
| SCHEMBL3334412 | 0.78 | CSNK2A1 (0.66) | KMT2AGAANPSR1CSNK2A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | KMT2A 1524/4885GAA 2254/4885NPSR1 4271/4885 |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, HGFAC | KMT2A 1909/4885GAA 2319/4885NPSR1 1296/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | KMT2A 1524/4885GAA 2254/4885NPSR1 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.